7月30日,百利天恒(688506)发布公告,公司收到国家药品监督管理局正式批准的《药物临床试验批准通知书》,其自主研发的创新生物药注射用BL-B01D1(皮下注射)治疗晚期实体瘤的临床试验获得批准。 注射用BL-B01D1(皮下注射)是在公司已有的伦康依隆妥单抗/宜泽康(BL-B01D1/iza-bren)基础上开发的皮下制剂,旨在缩短临床给药时长,提高给药便捷性。 值得注意的是,伦康依隆妥...
Source Link7月30日,百利天恒(688506)发布公告,公司收到国家药品监督管理局正式批准的《药物临床试验批准通知书》,其自主研发的创新生物药注射用BL-B01D1(皮下注射)治疗晚期实体瘤的临床试验获得批准。 注射用BL-B01D1(皮下注射)是在公司已有的伦康依隆妥单抗/宜泽康(BL-B01D1/iza-bren)基础上开发的皮下制剂,旨在缩短临床给药时长,提高给药便捷性。 值得注意的是,伦康依隆妥...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.